BAY.MI: Summary for BAYER - Yahoo Finance

UK Markets closed

Bayer Aktiengesellschaft (BAY.MI)

Milan - Milan Delayed price. Currency in EUR
Add to watchlist
113.00+0.10 (+0.09%)
At close: 5:14PM CEST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous close112.90
Bid0.00 x
Ask0.00 x
Day's range112.40 - 114.20
52-week range83.80 - 114.20
Avg. volume1,801
Market cap93.32B
PE ratio (TTM)20.77
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • American City Business Journals2 days ago

    Monsanto's image a 'major challenge' for Bayer: CEO

    Werner Baumann, CEO of Bayer AG, told shareholders Friday that improving Monsanto's reputation will present a challenge to Bayer following its planned $66 billion takeover of the company. "Monsanto's image does of course represent a major challenge for us, and it's not an aspect I wish to play down," Baumann said during the company's annual meeting, Reuters reports. Bayer and Monsanto announced their merger in September.

  • Reuters2 days ago

    Bayer CEO says Monsanto's reputation is a "major challenge"

    Bayer's chief executive acknowledged on Friday that he will face an uphill battle to improve Monsanto's reputation once Bayer completes the takeover of the U.S. seeds and agrochemicals company. "Monsanto’s ...

  • Reuters2 days ago

    FDA approves Bayer's Stivarga to treat most common liver cancer

    The U.S. Food and Drug Administration said on Thursday it has approved Bayer AG's drug Stivarga to treat liver cancer, the first such approval in nearly a decade. Stivarga is already approved to treat colorectal cancer in patients who have previously been treated with other therapies. About 40,710 people will be diagnosed with liver cancers in 2017 and about 28,920 will die of the diseases, according to the National Cancer Institute.